Investigational Study With the BD PosiFlush™ SafeScrub on NADs

NARecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

November 28, 2025

Study Completion Date

November 28, 2025

Conditions
CRBSI - Catheter Related Bloodstream Infection
Interventions
DEVICE

BD PosiFlush™ SafeScrub

"Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."

DEVICE

BD PosiFlush™

"Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."

Trial Locations (2)

4020

RECRUITING

Ordensklinikum Linz Elisabethinen, Linz

Unknown

RECRUITING

Medical University Vienna, Vienna

Sponsors
All Listed Sponsors
lead

Becton, Dickinson and Company

INDUSTRY